Abstract
Objective To investigate the effect and mechanism of ticagrelor on bradycardiac arrhythmia after percutaneous coronary intervention. Methods Ninety-six patients underwent percutaneous coronary intervention(PCI)were enrolled and divided into two groups randomly, clopidogrel group(n=48) and ticagrelor group(n=48). The patients in clopidogrel group were given 600 mg clopidogrel and the patients in ticagrelor group were given 180 mg ticagrelor at 1 hour before PCI. After operation, both were given 75 mg clopidogrel per days. The incidences of bradycardiac arrhythmia, platelet aggregation rate, the expression of hs-CRP and LP-PLA2 and adverse reaction were recorded at first day, seventh day and fourteenth day, respectively. Results The incidence of bradycardiac arrhythmia was significantly reduced in both groups at postoperative 1 st, 3 rd , 7 th day. Compared with clopidogrel group, the incidences of bradycardiac arrhythmia were significantly reduced in ticagrelor group at first day, seventh day and fourteenth day. In addition, the platelet aggregation rates also reduced at first day, seventh day and fourteenth day. Conclusions Ticagrelor can reduce the incidence of bradycardiac arrhythmia after percutaneous coronary intervention, which may be related with reduced platelet aggregation. Key words: Ticagrelor; Bradycardiac arrhythmia; Percutaneous coronary intervention; Platelet aggregation; Inflammatory response
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
